ADMA
ADMA clinical trials: ADMA BIOLOGICS, INC.
Every trial on ClinicalTrials.gov where ADMA BIOLOGICS, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 7
- Trials linked
- 7
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ADMA on the catalyst calendar · ADMA registry changes
- Primary completion Aug 30, 2022ActualPhase 4NCT03164967Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16ADMA Biologics, Inc. · Humoral Immune ResponseCompletedADMALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2022ActualNo phase registeredNCT03037359A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin ProductsADMA Biologics, Inc. · Primary Immune Deficiency DisorderUnknown statusADMALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2023Sponsor estimatePhase 4NCT05070455An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With...ADMA Biologics, Inc. · Primary Immune DeficiencyUnknown statusADMALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2009ActualPhase 3NCT00538915Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency...ADMA Biologics, Inc. · Primary Immune Deficiency Disorders (PIDD)CompletedADMALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2009ActualPhase 2NCT00473824Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver TransplantationADMA Biologics, Inc. · Sequelae of Viral HepatitisTerminatedADMALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2014ActualPhase 3NCT01814800Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)ADMA Biologics, Inc. · Primary Immune Deficiency DisorderCompletedADMALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2010ActualPhase 2NCT00632463RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV IllnessADMA Biologics, Inc. · Upper Respiratory Tract InfectionCompletedADMALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 7 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner